US-based medical device company Medtronic launched new drug-eluting stent (DES) technology Resolute Onyx for the first time in India. It has been introduced in Hyderabad, Kolkata, Kochi, Mumbai and will be launched in Bangalore and Delhi shortly. The technology is based on Resolute Integrity platform which offers flexibility in the form of sleek.
India is one of the largest contributors of CAD patients in the world with 25 million coronary artery disease (CAD) patients in 2015. Of this, only 1.6 million patients are treated with cardiac stents over the past 10 years. Cardiac stent therapy penetration in India is at 2.6 per cent of the diseased population. Angioplasties in India have been growing in double digits since 2001 with annually 300,000 cases.
Dr Peter Andreka, interventional cardiologist, Hungarian Institute of Cardiology, Hungary, said "Over the past 20 years, stents have evolved from a plain vanilla bare metal stent to new generation DES. Resolute Onyx DES is a revolution in stent technology. Resolute Onyx is the most deliverable DES, featuring Core Wire Technology. It has thinner struts to help improve deliverability without compromising radial and longitudinal strength of the stent. Resolute Onyx has proven long-term safety and efficacy with increased risk for stent thrombosis with interruption or discontinuation of DAPT after 1 month. Resolute Onyx DES builds on the Resolute Integrity platform’s acute procedural success for even greater flexibility and conformability."
He informed , "CoreWire Technology is the next new DES advancement after Continuous Sinusoid Technology (CST). Core Wire Technology combined with CST enables thinner struts without compromise in radiopacity or overall structural strength. Wrapped in a Cobalt Alloy shell, the denser, more radiopaque inner core material allows for improved visibility during procedure, referred to as radiopacity. The Cobalt alloy shell maintains the mechanical performance and structural strength of the stent material thus improving deliverability and acute performance."
Subscribe to PharmaTutor News Alerts by Email >>
